Culture Biosciences is a biotechnology company building the future of biomanufacturing. The company is pioneering biomanufacturing-as-a-service.
Culture Biosciences develops automated bioreactor infrastructures and runs it as a service for biotech companies.
Culture Biosciences was founded in 2016 by Will Patrick and Matt Ball. The company is headquartered in South San Francisco, California.
Culture Biosciences' vision is to make biomanufacturing a digital experience: we want running bioreactors to be as easy as running code in a data center.
Culture Biosciences has developed a digital biomanufacturing platform to enable scientists to run, monitor and analyze bioreactors faster and more conveniently than traditional approaches.
Culture's platform, which integrates best-in-class bioreactors, cloud monitoring capabilities and remote operations, is currently being used by leading biotechnology companies to optimize their R&D processes.
Culture Biosciences is backed by Section 32, Refactor Capital, Cultivian Sandbox Ventures, The Production Board and others. The company raised $15M in a Series A round on Mar 04, 2020. This brings Culture Biosciences' total funding to $20.6M to date.